U.S. Markets closed

Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix

CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. In addition, the volatility within the broader markets has pushed investors to look at traditional "safe haven" stocks and healthcare/biotechnology have long been seen as such. With this being the case, we're taking a closer look at 4 healthcare and biotech-related companies on Wednesday.

Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education. Furthermore, the Company is actively recruiting additional physicians for its existing clinics and a cannabis-focused physician that is licensed in Canada.

Premier Health Group, Inc. (PHGRF) (PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.

"With over 110,000 active patients in our clinic ecosystem it is important that we provide them with the best possible information that allows them to make informed decisions about their personal and family's health. Providing our family physicians with the appropriate tools and knowledge to prescribe cannabis or with the ability to refer patients to a specialist within our clinics is a key outcome of this initiative," said Dr. Essam Hamza, CEO of Premier.

For More Information On Premier Health Group, Click Here

Alliqua BioMedical, Inc. (ALQA) through its AquaMed subsidiary, can provide a custom manufacturing solution to partners in the medical device; cosmetics; and OTC industry, utilizing its proprietary hydrogel technology.

This morning the company along with TO Pharmaceuticals LLC announced plans for Alliqua to spin off its AquaMed Technologies, Inc. subsidiary, which develops, manufactures and markets high water content, electron beam cross-linked aqueous polymer sheet hydrogel products and merge it with TOP, creating a new public bio-pharmaceutical company to be called TO Pharma, focused on discovering, developing and commercializing novel therapeutics based on TOP's proprietary cannabinoid product platform in a number of FDA-regulated clinical indications and in select OTC markets.

Seth Yakatan, CEO of TOP, noted that "We are excited to combine TOP's technology and research with the unique capabilities of AquaMed's hydrogel technology, to form a truly global pharmaceutical company. We are excited and confident that the anticipated development of the combined business should generate significant shareholder value."

For More Information On Alliqua, Click Here

BioScrip (BIOS) is an independent national provider of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services.

Shares of the company jumped this morning after BioScrip announced that it will host an Analyst and Investor Day on Thursday, December 6, 2018 in Reston, Virginia.

Daniel E. Greenleaf, President and Chief Executive Officer, will provide an update of the Company's strategy and business, followed by a fireside chat with members of BioScrip's executive management team. Presentations will begin at 10:30 am ET and conclude between 12:00 pm and 12:30 pm ET.

BioScrip shares have already hit highs of $4.04 this morning.

For More Information On BioScrip, Click Here

Coremedix (NYSE American: CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in Phase 3 development for patients undergoing chronic hemodialysis.

Earlier this month the company announced financial results for the third quarter and nine months ended September 30, 2018 and provided an update on recent business developments.

"After the Data and Safety Monitoring Board recommended our LOCK-IT 100 trial be halted for efficacy, we began the methodical process of closing the study and are well on our way to completing locking the data set," said Khoso Baluch, Chief Executive Officer of CorMedix.

Shares of Cormedix jumped to highs of $1.34 on Wednesday morning after dropping to lows of $1.15 on Tuesday.

For More Information On Coremedix, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:


SOURCE: StockPrice.com